Issue 148

Using psilocybin in naturalistic settings shows lasting results

Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.

Carried out by research non-profit Unlimited Sciences and published in Frontiers in Psychiatry, the observational study represents the world’s largest longitudinal dataset on naturalistic psilocybin use to date.

Results reveal the broad therapeutic potential of a single dose of psilocybin in producing lasting improvements in mental health and wellbeing, consistent with the growing body of evidence from clinical trials.

Unlimited Sciences Executive Director and Chief Scientific Officer Matthew X. Lowe, Ph.D.,stated: “Outside of clinical research settings, psilocybin is capable of producing significant and persisting changes in psychological health and wellbeing, such as reductions in anxiety, depression and alcohol misuse.”

READ MORE

HOPE ON THE HORIZON FOR 2024 FDA APPROVAL OF MDMA THERAPY

MAPS PBC has published results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024.

Read More

PSYCHEDELICS SUPPORTED MENTAL HEALTH DURING COVID-19

A landmark survey has revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.

Read More

BUSINESS AND INVESTMENT

Hedge fund manager Steve Cohen has backed psychedelics with the purchase of over 18 million shares of Cybin, Inc. through his fund Point 72.

Clearmind Medicine has closed its US public offering at US$2.25 million which will go towards research and development.

The FDA has approved two of Filament Health’s clinical trials to study the company’s botanical psilocybin drug candidate for mental health conditions.

Numinous Pathways has ceased operations at Numinous Bioscience and consolidated two clinics to accelerate its path to profitability.

BioMind Labs has completed the development of the first 5-MeO-DMT organic synthesis scheme, ensuring efficient production and high purity of the compound.

Mydecine Innovations has closed its financing round, aiming to raise $3.75 million towards its listing on the CSE.

Would your organisation benefit from engaging Europe's psychedelic medicine community?

Partnership with Psychedelic Health provides the opportunity to engage an audience ready to support the development of psychedelic medicine.

For more information and to request the media kit, please email stephanie@psych.global

REQUEST MEDIA KIT

SCIENCE AND RESEARCH

Understanding the study that shook psychedelic science. A recent University of Helsinki study revealed psychedelics to have high binding affinity to TrkB receptors.

Ketamine can offer rapid relief from anxiety, according to a new meta-review published in the Journal of Psychopharmacology. 

REGULATION AND LEGISLATION

The European Medicines Agency has added a section on psychedelic therapy to its general guidelines for the development of medicines for major depression.

A new congressional bill – the VISIONS Act – has been introduced that aims to protect the legal use of psilocybin from federal prosecution in states where the compound is legal.

ARTICLES OF INTEREST

People in the UK are struggling with their mental health due to the cost of living crisis, with 24% of survey respondents saying the crisis has impacted them as much as the COVID-19 pandemic.

The European Parliament’s subcommittee on public health has emphasised the need to identify vulnerable populations in order to treat mental health.

Partner with us